Novartis receives first ever FDA approval for a CAR-T cell therapy
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
CAR T-Cell Therapy Hits Prime Time; Challenges Remain
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites | Cell Death & Disease
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy | Journal of Law, Medicine & Ethics | Cambridge Core